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Effects of low-dose flosequinan on left 
ventricular systolic and diastolic chamber 
performance 
Flosequinan (manoplax) is a new vasodilating agent for the treatment of congestive heart failure. 
Although it may have several mechanisms of action, whether it has effects on left ventricular 
inotropic or luisotropic events in hemodynamically relevant low doses when added to standard 
therapy for congestive heart failure is unknown. Ten patients with dilated congestive 
cardiomyopathy who were receiving standard therapy for heart failure were studied. A bipolar 
right atrial pacing catheter was used to maintain a constant heart rate. A 7F thermodilution 
catheter was used to measure right heart pressures and obtain cardiac outputs. An 8F 
micromanometer catheter was used to measure left ventricular and ascending aortic pressures. 
Gated equilibrium radionuclide angiography was performed both before and during a 
steady-state infusion of flosequinan. The average flosequinan infusion rate was 2.03 + 0.85 
mg/min, and the total administered dose averaged 84 +- 35 mg. The hemodynamic data 
documented substantial systemic vasodilation manifest by a reduction in right atrial pressure 
(p = O.Ol), mean pulmonary artery pressure (p < O.OOOl), pulmonary capillary wedge pressure 
(p < O.OOOl), and left ventricular end-diastolic pressure (p < 0.0001). These hemodynamic 
changes were associated with increases in cardiac index (p = 0.01) and left ventricular ejection 
fraction (p = 0.02) and reductions in mean aortic pressure (p = 0.02), systemic vascular 
resistance (p = O.Ol), and left ventricular volumes (p < 0.05). There was, however, no significant 
effect on left ventricular contractile function measured by end-systolic pressure-volume 
relationship (Em&, E,,, corrected for the change in left ventricular volume, or preload recruitable 
stroke work (I&,,). In contrast, there was an improvement in isovolumic relaxation manifest by an 
increase in maximum rate of fall of left ventricular pressure standardized for left ventricular 
end-systolic pressure [(-)dP/dt,&Pe.]; p = 0.02), an acceleration in the rate of isovolumic 
relaxation (p = O.Ol), and an improvement in left ventricular chamber stiffness (p = 0.02). These 
data indicate that when flosequinan, a new therapeutic agent for the treatment of congestive 
heart failure, is administered in hemodynamicaily relevant low doses to patients with dilated 
congestive cardiomyopathy who were receiving standard therapy for heart failure, left ventricular 
pump function and diastolic function is further improved. There was, however, no significant 
effect on left ventricular contractility. This study emphasizes that new therapeutic agents like 
fiosequinan, when administered in lower doses to avoid the potential deleterious effects of 
enhanced inotropy, may be useful additions to standard therapy in patients with congestive heart 
failure. (AM HEART J 1994;128:124-33.) 
Mark R. Starling, MD Ann Arbor, Mich. 
Flosequinan (manoplax) is a newly developed, orally 
active, 7-fluorinated quinoline that has unique va- 
sodilator properties on both the systemic venous and 
arterial circu1ations.l Several mechanisms for this 
vasodilating action of flosequinan have been pro- 
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posed.2 Some investigations have also suggested that 
this agent may have weak inotropic potential result- 
ing from nonspecific phosphodiesterase inhibition.’ 
Clinical studies in which flosequinan was adminis- 
tered to patients with congestive heart failure have 
demonstrated hemodynamic improvement consis- 
tent with the predominant systemic venous and ar- 
terial vasodilating properties of this therapeutic 
agent.4 These hemodynamic improvements appear to 
also be associated with improvements in clinical 
symptoms and exercise tolerance.5 Although it is as- 
sumed that the major beneficial hemodynamic ef- 
fects of flosequinan in patients with congestive heart 
failure are related to a vasodilating action, they may 
also be the result of weak inotropic or luisotropic ac- 
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tions. There is evidence in human beings that this 
weak inotropic effect may be evident at higher doses 
of flosequinan,6 but the benefits of flosequinan to pa- 
tients with congestive heart failure may be predom- 
inantly related to the additive vasodilating potential 
of the agent rather than the inotropic effects ob- 
served at higher doses, which may be detrimental in 
some patients with congestive heart failure. Accord- 
ingly, this investigation was undertaken to determine 
whether hemodynamically relevant low doses of 
flosequinan have beneficial effects on left ventricular 
systolic and diastolic chamber performance in addi- 
tion to their known systemic venous and arterial va- 
sodilating action in a select group of patients with 
dilated congestive cardiomyopathy, who were receiv- 
ing standard therapy for heart failure. 
METHODS 
Patients. The patient population consisted of 10 men 
with dilated congestive cardiomyopathy who ranged in age 
from 42 to 67 years (mean 53 + 10 years). All patients had 
normal sinus rhythm, had never experienced an ischemic 
myocardial event, had a gated equilibrium radionuclide 
angiogram demonstrating a left ventricular ejection frac- 
tion of ~0.40, and had normal coronary anatomy at cardiac 
catheterization. All patients had been receiving a stable 
therapeutic regimen of digitalis, a diuretic, and an an- 
giotensin-converting enzyme inhibitor for at least 2 months. 
No patients were in New York Heart Association clinical 
class I, 2 were in class II, 8 were in class III, and none were 
in class IV. Each patient provided written informed con- 
sent for this protocol on forms approved by either the In- 
stitutional Review Board at the University of Michigan 
Medical Center or the Human Studies Committee at the 
Veterans Affairs Medical Center in Ann Arbor, Mich. 
Protocol. After diagnostic right and left heart catheter- 
izations, each patient entered the protocol. A bipolar pac- 
ing catheter was placed in the right atrial appendage to 
maintain a constant heart rate. A 7F thermodilution cath- 
eter was used to perform a right heart catheterization, and 
it remained in the pulmonary artery throughout the proto- 
col. Both the proximal and distal ports were connected to 
fluid transducers to measure pulmonary artery, pulmonary 
capillary wedge, and right atrial pressures. An 8F micro- 
manometer catheter (SPC-784A, Millar Instruments, Inc., 
Houston, Texas) was calibrated and positioned in the left 
ventricle to measure both left ventricular and ascending 
aortic pressures. In vivo red blood cell labeling with 30 to 
35 mCi of technetium 99m was achieved for gated equilib- 
rium radionuclide angiography. A gamma scintillation 
camera was brought into the cardiac catheterization labo- 
ratory and positioned to optimally separate the right and 
left ventricles in the plane of the interventricular septum. 
Each patient was allowed to equilibrate; right and left 
heart pressures were recorded, and thermodilution cardiac 
outputs were obtained in triplicate. Micromanometer left 
ventricular and aortic pressures and gated equilibrium ra- 
dionuclide angiograms were acquired under control condi- 
tions and during methoxamine or nitroprusside infusions 
to obtain two additional steady-state left ventricular load- 
ing conditions. 
After completing this phase of the protocol, each patient 
was allowed to return to baseline, which was defined as 
pressure within 10 % of the original baseline hemodynamic 
pressures. All pressures and cardiac outputs were repeated. 
A steady-state intravenous infusion of flosequinan was be- 
gun and incrementally increased to achieve a 5 mm Hg de- 
crease in pulmonary capillary wedge pressure or a 20 mm 
Hg decrease in left ventricular systolic pressure. Once one 
of these hemodynamic end points was reached, the right 
and left heart pressures and cardiac outputs were repeated, 
blood samples were drawn for drug levels, and the micro- 
manometer pressures and radionuclide angiograms were 
again acquired under basal conditions and during methox- 
amine or nitroprusside infusions to obtain two additional 
steady-state left ventricuIar loading conditions. The aver- 
age flosequinan infusion rate was 2.03 + 0.85 mg/min with 
a range of 0.67 to 3.5 mg/min for a total administered dose 
of 84 + 35 mg (range 53 to 125 mg). 
After this phase of the protocol was completed, the 
flosequinan infusion was discontinued. Right and left heart 
pressures and cardiac outputs were repeated 15 minutes 
after completion of the flosequinan infusion, and a final 
blood sample was drawn for drug levels. All 10 patients 
completed the protocol without complications. 
Hemodynamics. At each point during the protocol, 
phasic and mean right atrial, pulmonary artery, and 
pulmonary capillary wedge pressures were recorded. Car- 
diac outputs were performed in triplicate with the ther- 
modilution technique. Micromanometer left ventricular 
and aortic pressures were recorded at 100 mm/set paper 
speed. The micromanometer left ventricular pressures 
were digitized as previously described from this laborato- 
ry7 and interpolated to provide corresponding left ventric- 
ular pressures for each radionuclide left ventricular volume 
determination. 
Radionuclide angiography. Gated equilibrium radio- 
nuclide angiograms were acquired and processed as previ- 
ously described from this laboratory.sp g Each radionuclide 
angiogram was acquired into 30 msec frames for 250 cardiac 
cycles. During the midportion of each radionuclide acqui- 
sition a 2 ml blood sample was drawn and the time 
recorded. Blood samples were later counted for 2 min and 
the time delay recorded for decay correction. At completion 
of the study, distance measurements were made for each 
patient to determine the distance from the left ventricle to 
the gamma scintillation camera for attenuation correction. 
Left ventricular volumes were calculated on a frame-by- 
frame basis with background-subtracted hand-drawn re- 
gion-of-interest left ventricular count data, decay-cor- 
rected blood sample counts, and attenuation correction.8 
Data analysis. Cardiac index was calculated by dividing 
cardiac output by body surface area. Stroke volume index 
was calculated by dividing CI by the corresponding heart 
rate. Mean aortic pressure was obtained by adding one 
third of the aortic pulse pressure to the aortic diastolic 
pressure. Left ventricular stroke work index was obtained 
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Fig. 1. Calculation of left ventricular chamber elastance and left ventricular diastolic chamber constant 
are shown for representative patient with dilated congestive cardiomyopathy. Micromanometer left ven- 
tricular pressures are plotted on ordinant and radionuclide left ventricular volumes are plotted on abscissa. 
Multiple pressure-volume loops are generated and maximum left ventricular chamber elastance (E,,,), a 
relatively load-independent index of left ventricular contractility (solid line), and left ventricular diastolic 
chamber compliance (k, dashed line) were calculated as shown from these data. 
by multiplying mean aortic pressure by stroke volume in- 
dex; the result was multiplied by 0.0136 to convert from 
millimeters of mercury per milliliter per square meter to 
gram-meters per square meter. Systemic vascular resis- 
tance was calculated by multiplying the difference between 
mean aortic and right atria1 pressure by cardiac output and 
multiplying the result by 80 dynes . set . cme5. 
Left ventricular systolic function was assessed in several 
ways. We evaluated the isovolumic phase of systole by cal- 
culating the maximum rate of increase of left ventricular 
pressure [(+)dP/dt,,,J).’ We also assessed several other 
ejection phase and contractile indexes. Left ventricular 
ejection fraction was calculated in the standard fashion by 
using the radionuclide left ventricular end-diastolic and 
end-systolic volumes. Corresponding micromanometer left 
ventricular pressures and radionuclide left ventricular vol- 
umes were plotted to generate multiple pressure-volume 
loops (Fig. 1). The pressure-volume loops from the basal 
condition and during the steady-state flosequinan infusion 
were subjected to calibrated planimetry. These areas were 
multiplied by 0.0136 to convert from millimeters of mer- 
cury per milliliter to gram-meters. Because left ventricular 
stroke work is preload dependent,“’ we plotted the left 
ventricular stroke work values from each pressure-volume 
loop against their corresponding left ventricular end-dia- 
stolic volumes to obtain a slope reflective of preload 
recruitable stroke work (M,, Fig. Z), an index of left ven- 
tricular contractility. We also used left ventricular cham- 
ber elastance, another relatively load-independent index of 
left ventricular contractility.ll-r* By using the multiple 
pressure-volume loops generated under the basal condition 
and during the steady-state flosequinan infusion, isoch- 
ronal pressure-volume points were subjected to linear re 
gression analyses to obtain a maximum slope, E,, (Fig. 1) 
Because E,,, can be affected by left ventricular size,15-17 WC 
subjected the E,,, values to a mathematical correction tc 
adjust for the contribution of changes in heart size on E,, 
Left ventricular diastolic function was assessed in severa 
ways. Left ventricular isovolumic relaxation was evaluate< 
by using left ventricular maximum rate of fall of left ven 
tricular pressure [(-)dP/dt,iJ. Because this index of iso 
volumic relaxation is pressure dependent,ls (-)dP/dt,i, 
was standardized to the micromanometer left ventricular 
pressure (P,,) at (-)dP/dfi, [(-)dP/dt,&‘es]. We also 
quantitated the effects of flosequinan on the rate o: 
isovolumic pressure decline over the time from (-)dP/dt 
,,,h to 5 mm Hg above left ventricular end-diastolic pressun 
of the next beat using the method of Weiss et al.,lg, 2o whick 
is given by the equation P(t) = P,eetD. The natural loga. 
rithmic transformation of this equation yields 1nP = -It/ 
T + lnP,, where the time constant (Tau) is the negative 
reciprocal of the slope (-l/T). Finally, we evaluated left 
ventricular chamber stiffness.21 This index was obtained by 
using nonlinear regression of the corresponding microma- 
nometer left ventricular end-diastolic pressures and radi- 
onuclide left ventricular end-diastolic volumes to obtain a 
chamber stiffness constant (Fig. 1). 
Pharmacologic assay. Flosequinan and BTS 53,554, 
the active metabolite of flosequinan, were assayed from 
plasma samples by the method of Slegowski et a1.,22 which 
was modified to use two overlapping standard curves to di- 
minish variance at the lower range of detection. The high 
range was 0,200,500,2000,3333, and 5000 rig/ml, and the 
low range was 0,50,100,200, and 500 rig/ml of either flose- 
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Fig. 2. Representative example of calculation of preload recruitable stroke work is shown. Left ventric- 
ular stroke work (SW) values are plotted on ordinate and left ventricular end-diastolic volumes (E’DV) are 
plotted on abscissa over full range of loading conditions. Slope reflects preload recruitable stroke work 
f&f&, a relatively load-independent index of left ventricular contractility. 
Table I. Hemodynamics (n = 10) 
Baseline 
With 
flosequinan P Value 
HR (beats/min) 87 + 10 
RAP (mm Hg) 9i2 
MPAP (mm Hg) 31 f 9 
PCWP (mm Hg) 21 + 10 
CI (L/min/m2) 2.61 2 0.78 
SVI (ml/m2) 30 k 9 
LVSP (mm Hg) 122 t 25 
LVEDP (mm Hg) 28 k 5 
AoP (mm Hg) 91 f 12 
SW1 (g-m/m2) 30 t 12 
SVR (dynes . set . cmm5) 1328 k 528 
PVR (dynes set . cmm5) 167 + 123 
88 + 9 0.37 
8k2 0.01 
23 +- 10 <O.OOol 
12 + 9 <O.OOOl 
2.82 k 0.67 0.01 
32 + 8 0.04 
115 f 21 0.06 
16 + 8 <0.0001 
84 1- 11 0.02 
32 k 11 0.13 
1108 +- 341 0.01 
155 + 73 0.58 
HR, heart rate; RAF’, right atrial pressure; MPAP, mean pulmonary artery pressure; PC WP, pulmonary capillary wedge pressure; CI, cardiac index; SVI, 
stroke volume index; LVSP, left ventricular systolic pressure; LVEDP, left ventricular end-diastolic pressure; AC@, mean aortic pressure; SWI, stroke work 
index; SVR, systemic vascular resistance; PVR, pulmonary vascular resistance. 
quinan or BTS 53,554. The standard curves for both ranges 
of flosequinan were linear (r = 0.999), with a slope of I841 
or 1842 rig/ml, a coefficiency of variation of 1.5%, and a 
mean SEE of 32.7 rig/ml equivalents for the high range and 
4.8 rig/ml equivalents for the low range. The interbatch 
sample recovery for 50 rig/ml samples was 108.7% with a 
coefficiency of variation of 7.9 % . Intrabatch recovery and 
coefficiency of variation were 100.6% and 11.8%, respec- 
tively. All values for BTS 53,554 were comparable; thus the 
assay had acceptable precision and accuracy down to 50 
rig/ml for both flosequinan and its metabolite. 
Statistical analysis. All data are presented as the 
mean + SD. Continuous variables were compared by 
paired t tests. Differences were statistically significant 
when a probability value of 50.05 was obtained. 
RESULTS 
Hemodynamic data. The hemodynamic data during 
the baseline condition and the steady-state flose- 
quinan infusion are shown in Table I. Heart rate was 
unchanged as a result of right atria1 appendage pac- 
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Fig. 3. Left, Individual and mean left ventricular chamber elastance (Ema3 values at baseline and during 
steady-state flosequinan (Flos) infusion are shown. Right, Individual and mean E,, values after correc- 
tion for changes in left ventricular end-diastolic volume are also shown. Differences in individual responses 
are evident, and average E,, and E,, corrected for end-diastolic volume (Corr Ema3 were not affected. 
Table il. Left ventricular chamber performance and ventriculo-arterial coupling relations 
Baseline 
With 
flosequinan P Value 




E,, (mm Hg/ml) 
E CORR (mm Hg/ml) 
Myz(gm-m/ml) 
(-)dP/dt,i, (mm Hg/sec) 
(-)dP/dtn&‘,, (set-l) 
Tau (msec) 
k (mm Hg/ml) 
1143 f 382 1201 + 624 0.65 
461 f 210 382 + 174 0.03 
345 f 173 268 + 142 0.02 
0.27 f 0.07 0.32 f 0.10 0.02 
0.45 f 0.30 0.76 + 0.70 0.07 
1.01 + 0.61 1.45 f 1.14 0.06 
0.24 f 0.15 0.38 f 0.26 0.08 
1060 + 244 1283 + 510 0.09 
15 f 4 19 I!I 6 0.02 
67 + 17 53 + 13 0.01 
0.07 f 0.04 0.05 + 0.05 0.02 
(+Wl&,,, maximum rate of rise of left ventricular pressure; EDV, end-diastolic volume; ESV, end-systolic volume; EF, ejection fraction; MS,, preloac 
recruitable stroke work; I$,,,,,, end-systolic pressure-volume relationship; E,,, CORR, end-systolic pressure-volume relationship corrected for volume 
(-)dP/dt,i,, maximum rate of fall of left ventricular pressure; (-)dP/dt,JP,,, maximum rate of fall of left ventricular pressure standardized for left ven 
tricular end-systolic pressure; Tau, isovolumic relaxation rate; k, left ventricular diastolic chamber stiffness. 
8 t- 2 mm Hg (p = 0.01). The mean pulmonary artery 
pressure fell from 31 -I- 9 to 23 + 10 mm Hg (p < 
O.OOOl), and the mean pulmonary capillary wedge 
pressure was reduced from 21 + 10 to 12 + 9 mm Hg 
(p < 0.0001). The cardiac index increased 
(2.61 -+ 0.78 to 2.82 + 0.67 L/min/m2, p = O.Ol), as 
did the stroke volume index (30 f 9 to 32 + 8 ml/m2, 
p = 0.04). Left ventricular systolic pressure was mar- 
ginally affected (122 f 25 to 115 + 21 mm Hg, 
p = 0.06), and left ventricular end-diastolic pressure 
was reduced from 28 + 5 to 16 + 8 mm Hg 
(p < 0.0001). Despite a marginal effect on left ven- 
tricular systolic pressure, mean AoP decreased fron 
91 f 12 to 84 f 11 mm Hg (p = 0.02). Consequently 
although left ventricular stroke work was unaffected 
systemic vascular resistance decreased fron 
1328 + 528 to 1108 + 341 dynes . set . cmm5 (p = 
O.Ol), and pulmonary vascular resistance was un- 
changed. 
Left ventricular systolic function. The effects oi 
flosequinan on left ventricular systolic function are 
shown in Table II. The left ventricular (+)dP/dt,, 
was not affected by the flosequinan infusion. Left 
ventricular end-diastolic and end-systolic volumes 
volume 128, Number 1 
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were reduced (p = 0.03 and p = 0.02, respectively), 
which lead to an increase in left ventricular ejection 
fraction from 0.27 + 0.07 to 0.32 f 0.10 (p = 0.02). 
However, left ventricular SW1 did not increase with 
the flosequinan infusion. 
When the relatively load-independent, end-sys- 
tolic index of left ventricular contractility, Em=, was 
assessed, no significant improvement was noted. The 
individual and mean values for E,, are shown in Fig. 
3. The average value increased from 0.45 f 0.30 to 
0.76 +- 0.70 mm Hg/ml (p = 0.07). The data in Fig. 3 
show that these mean values were substantially 
affected by two patients who had marked increases in 
left ventricular chamber elastance, whereas 8 of the 
10 patients had little or no change in E,,,. Because 
E may have been affected by the changes in left 
vem?ricular size induced by flosequinan, the individ- 
ual E,,, values were adjusted for the effects of the 
changes in heart size, and they also showed a mar- 
ginal but insignificant change (1.01 + 0.61 to 1.45 + 
1.14 mm Hg/ml, p = 0.06). Because E,,, can be 
affected by heart size and can be nonlinear in these 
low contractile ranges, preload recruitable SW was 
also used to assess left ventricular contractility. As 
shown in Table II, this contractile index was also not 
significantly affected by flosequinan in the doses used 
in this investigation (0.24 f 0.15 vs 0.38 t 0.26 gm- 
m/ml, p = 0.08). 
Left ventricular diastolic function. The effects of 
tlosequinan on left ventricular diastolic function are 
also shown in Table II. Left ventricular (-)dP/d&, 
was not affected by the flosequinan infusion. How- 
ever, because left ventricular pressure was reduced, 
when (-)dP/dt,i, was standardized to P,, at (-)dP/ 
dtmim the isovolumic pressure decay significantly ac- 
celerated from 15 f 4 to 19 + 6 see-l (p = 0.02). 
This was confirmed by an acceleration in Tau from 
67 ? 17 to 53 + 13 msec (p = 0.01, Fig. 4). All pa- 
tients demonstrated a systematic acceleration in the 
rate of isovolumic pressure decline. Left ventricular 
chamber stiffness was also improved by the flose- 
quinan infusion. The left ventricular chamber stiff- 
ness constant (k) was reduced from 0.07 +- 0.04 to 
0.05 + 0.05 mm Hg/ml (p = 0.02, Fig. 5). With one 
exception, all patients studied demonstrated a sys- 
tematic reduction in left ventricular chamber stiff- 
ness, as is illustrated for a representative patient in 
Fig. 5. 
Pharmacologic factors. Flosequinan and single ma- 
jor active metabolite BTS 53,554 plasma levels sub- 
stantially varied in these patients with congestive 
heart failure. The peak flosequinan plasma level 











Fig. 4. Left, Individual and mean Tau values at baseline 
and during steady-state flosequinan (Flos) are shown. Sys- 
tematic reductions in individual values are evident. 
and the BTS 53,554 plasma level varied between 0 
and 552 rig/ml (426 & 232 rig/ml). 
DISCUSSION 
Flosequinan is a new therapeutic agent for the 
treatment of congestive heart failure, which has 
mixed systemic venous and arterial vasodilating ac- 
tion. Although the specific mechanisms of action of 
flosequinan are unclear, it is apparent that the 
mechanisms by which flosequinan exerts these ben- 
eficial hemodynamic effects differ from those of 
therapeutic agents currently in use for the treatment 
of congestive heart failure. Data from rat aortic 
smooth-muscle preparations demonstrate that the 
concentration of flosequinan required to block 50% 
of a norepinephrine-induced contraction is substan- 
tially less than that needed to produce a comparable 
reduction in a potassium chloride-induced contrac- 
tion.23 These data suggest that flosequinan may have 
a greater effect on modification of intracellular cal- 















Fig. 5. Left, Individual and mean left ventricular (LV) chamber compliance values are shown in similar 
format. Systematic reductions in individual left ventricular chamber compliance constant are evident. Sig- 
nificant difference is noted. Right, Representative example from patient with dilated congestive cardiomy- 
opathy of left ventricular diastolic chamber stiffness is shown under baseline conditions and during 
steady-state flosequinan (Flos) infusion. Downward displacement with flattening of chamber compliance 
curve is evident. L VEDP, Left ventricular end-diastolic pressure; L VED V, left ventricular end-diastolic 
volume. 
Further studies from the rat aortic preparation 
demonstrate that flosequinan can relax contractions 
induced by phorbol dibutyrate.24 Because phorbol 
dibutyrate-induced contractions occur through the 
stimulation of protein kinase C, it has been suggested 
that flosequinan may prevent the stimulation of pro- 
tein kinase C as an alternative mode of action. How- 
ever, the concentrations of flosequinan required to 
produce 50 % relaxation of a phorbol dibutyrate con- 
traction are greater than those needed to produce a 
similar block of a norepinephrine contraction in the 
same preparation, suggesting that this mechanism 
may also be less important than the effects of flose- 
quinan on intracellular calcium handling. 
More recent studies performed with the rat aortic 
preparation demonstrate that flosequinan prevents 
the production of inositol 1,4,&triphosphate and to 
a lesser extent protein kinase C activation produced 
by endothelin-1 effector-receptor coupling.25 These 
data coupled with prior data23p24p26 suggest that 
flosequinan may block the effector-receptor acti- 
vation of G transduction proteins which, in the pres- 
ence of guanosine triphosphate, stimulate phospho- 
lipase C. Activation of membrane-bound phospholi- 
pase C catalyzes the hydrolysis of phosphoinositides 
to the secondary messengers inositol 1,4,5-triphos- 
phate and diacylglycerol. Inositol 1,4,&triphosphate 
increases intracellular calcium levels by releasing 
calcium from intracellular stores; diacylglycerol does 
so by stimulating protein kinase C to increase trans- 
membrane calcium transients. Thus it can be postu- 
lated that flosequinan may act in vascular smooth 
muscle by blocking the production of secondary 
messengers, either at the transduction protein level 
or by the activation of phospholipase C. 
These mechanisms of action may explain the sys- 
temic venous and arterial vasodilating action ob- 
served with flosequinan; however, there are addi- 
tional possible mechanisms of action for flosequinan 
on myocardial tissue. 3y 27 In guinea pig left ventricu- 
lar myocardium, flosequinan in high concentrations 
has caused an increase in cyclic adenosine mono- 
phosphate and guanosine monophosphate. These 
data suggest that flosequinan may have an effect on 
phosphodiesterase activity. Although this effect was 
noted only at high concentrations of flosequinan, it 
does suggest that flosequinan may have a positive in- 
otropic effect on myocardial tissue. There have been 
several studies in human beings that have resulted in 
conflicting conclusions regarding the inotropic po- 
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tential of flosequinan.6t 28, 2g Initially, Haas et a1.28 
studied 10 patients with congestive heart failure be- 
fore and after the administration of 100 mg of flose- 
quinan. They observed favorable alterations in load- 
ing conditions that improved left ventricular pump 
function, but inotropic parameters did not change 
significantly compared to placebo. Subsequently, 
Corin et a1.2g studied a similar group of 10 patients 
with congestive heart failure and noted that there 
was a modest but significant increase in dP/dt,, of 
approximately 10 % . More recently, Burstein et a1.6 
studied 18 patients with congestive heart failure. 
They administered 150 mg of flosequinan and noted 
an increase of approxima.tely 15 % in dP/dt,,,. They 
also noted an upward and leftward displacement of 
a single pressure-volume loop in several of their pa- 
tients after, flosequinan administration, which also 
suggested an enhancement in inotropy. Thus these 
data suggest that at doses of ~100 mg of flosequinan 
there is a modest inotropic effect, although not all 
data concurs. 
Our investigation was undertaken to establish 
whether flosequinan had effects on left ventricular 
systolic and diastolic performance in addition to its 
systemic vasodilating action in a well-defined patient 
population with dilated congestive cardiomyopathy 
when flosequinan was administered in lower doses to 
produce modest hemodynamic effects. The data from 
this investigation indicate that when used with a 
standard therapeutic background, flosequinan had 
significant effects on systemic venous capacitance, 
arterial resistance, and left ventricular diastolic func- 
tion at an average dose of 84 mg. In contrast, at these 
lower doses, flosequinan had no effect on left ven- 
tricular contractile function. By examining Fig. 3, 
two patients had a marked increase in their E,,, val- 
ues, and the remaining eight patients had little or no 
change in their E,, values. The two patients with 
enhanced inotropy both received >lOO mg of flose- 
quinan. This suggests either that there may be 
differences in individual patient responses to flose- 
quinan because these two patients with enhanced in- 
otropy had more mild contractile impairment or 
there is a dose-response effect of inotropy to flose- 
quinan. 
The observation that left ventricular active and 
passive relaxation were improved with flosequinan 
was unexpected. Recently it has been shown that, in 
patients with congestive heart failure and impaired 
left ventricular chamber elastance, left ventricular 
isovolumic relaxation has a wide range of impairment 
and therefore may be more sensitive to therapeutic 
intervention in these kinds of patients than left ven- 
tricular contractile function.30 There are several pos- 
sible explanations for this effect of flosequinan on left 
ventricular diastolic function, Coronary blood flow, 
although normal at rest, may be reduced per unit 
mass in patients with congestive heart failure, mak- 
ing the subendocardium more susceptible to myo- 
cardial ischemia.31, 32 Myocardial ischemia can pro- 
duce delayed and incomplete relaxation, which can 
lead to impaired chamber distensibility.33 Flose- 
quinan may have had a beneficial effect on these he- 
modynamic processes through a coronary vasodilat- 
ing action. However, recent data from Cavero et a1.34 
in patients with congestive heart failure demon- 
strated that flosequinan in oral doses of 100 mg did 
not change myocardial oxygen consumption, alter 
coronary sinus blood flow, or affect lactate produc- 
tion, suggesting that this is an unlikely possibility for 
the improvement in diastolic function. 
Alternatively, by decreasing left ventricular size 
and by enhancing left ventricle pump function, 
flosequinan may have reduced plasma norepineph- 
rine and transmyocardial norepinephrine flux, up- 
regulating P-receptors, improving receptor-effector 
coupling to G proteins and cyclic adenosine mono- 
phosphate production and thus stimulating more ef- 
ficient intracellular calcium handling. Alternatively, 
the direct effects of flosequinan on intracellular cal- 
cium handling may have improved isovolumic relax- 
ation. An explanation for the improvement in left 
ventricular chamber compliance may be a reduction 
of extrinsic restraint or ventricular interaction. This 
would seem most likely and would be consistent with 
the effect observed in this homogeneous group of pa- 
tients with dilated congestive cardiomyopathy. Car- 
roll et a1.35 showed that, in contrast to the effects of 
inotropic agents on chamber compliance, vasodila- 
tors cause a downward displacement of the diastolic 
pressure-volume curve consistent with relief of peri- 
cardial restraint or reduction in ventricular interac- 
tion. Further, a recent observation by Eichhorn et 
a1.36 suggests that the explanation for changes in left 
ventricular end-diastolic pressure seen in patients 
like ours with congestive heart failure may be the re- 
sult of both changes in isovolumic relaxation and 
chamber compliance. Whichever of these mecha- 
nisms are operative, flosequinan was shown in this 
investigation to have a beneficial effect on both of 
these measures of left ventricular diastolic function. 
The observation has been made that, most patients 
with congestive heart failure treated with Nose- 
quinan have an improvement in exercise tolerance 
when compared to placebo.5 For example, in a dou- 
ble-blind placebo controlled study to establish the 
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effects of flosequinan on exercise tolerance,37 symp- 
tomatic status and exercise time improved signifi- 
cantly when compared to placebo 0, < 0.05 for both). 
Moreover, exercise capacity is improved with flose- 
quinan in patients with congestive heart failure 
without activation of the neurohumoral system.38 
These beneficial effects may be related in part to the 
improvement in left ventricular diastolic dysfunction 
that was evident with flosequinan in this investiga- 
tion. Thus these data suggest that the addition of 
flosequinan in low doses might be valuable in patients 
with congestive heart failure on a conventional ther- 
apeutic regimen by improving both systemic hemo- 
dynamics and left ventricular diastolic function and 
thus symptomatic status and exercise tolerance. 
In conclusion, flosequinan is a new therapeutic 
agent for the treatment of congestive heart failure. 
Flosequinan has a mechanism of action that proba- 
bly differs from other therapeutic agents currently 
available. By inhibition of the activation of trans- 
duction proteins or phospholipase C, substantial 
systemic venous and arterial vasodilation occurs. 
Flosequinan also has an unexpected beneficial effect 
on left ventricular diastolic function that may be re- 
lated to improved isovolumic relaxation or diminish- 
ment of restraint on the left ventricle; however, 
flosequinan has no significant effect at these lower 
doses on left ventricular contractility. This study 
emphasizes that new therapeutic agents like flose- 
quinan may have a useful additive role to standard 
therapy in patients with congestive heart failure at 
lower doses where the potentially harmful effects of 
enhanced inotropy are not observed. 
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Prognostic value of echocardi phy in 
children with idiopathic dilated 
cardiomyopathy 
Mortality of pediatric patients with idiopathic dilated cardiomyopathy (IDC) is highest during the 
first 1 to 2 years the child is first seen. The echocardiograms of 72 infants and children with IDC 
were reviewed to determine whether left ventricular shortening fraction (LVSP), end-diastolic 
dimension, and wall mass were helpful in predicting outcome. Patients who were alive at last 
follow-up (group 1) were compared to those who died or required heart tranapfant (group 2). 
None of the indexes obtained at first examination were predictive of survival. shortening fraction 
had improved significantly at follow-up 1 to 6 months after first examination in group 1 
(15.1 + 0.9 to 24.4 k 1.8, p < 0.001) but remained unchanged in group 2 (14.1 + 1.5 to 
15.3 of: 3.2). No significant trends were noted in left ventricular end-dhstolk dimension or wall 
mass. The I- and J-year actuarial survival for all’patients was 75% and Ml%, respectfvely. 
Persistent depression of LVSF ~15% was associated with a signiffoantfy lower survival rate 
(l-year 46%; 5-year 29%) compared to patients in whom follow-up LVSF was >15% (l-year 97%; 
5-year 90%; p < 0.05). It is concluded that the follow-up LVSF obtained at least 1 month after 
first examination is helpful in identifying pediatric patients who would benefit from early cardiac 
transplantation. (AM HEART J 1994;128:133-6.) 
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children with idiopathic dilated cardiomyopathy 
(IDC) have been well described.l-s Mortality is high- 
Reprint requests: Alan B. Lewis, MD, Division of Cardiology, Mail Stop 34, 
Children6 Hospital Los Angeles, PO Box 54700, Los Angeles, CA 90054. 
0700. 
Copyright g’ 1994 by Mosby-Year’Book, Inc. 
000%8703/94/$3.00 + 0 4/l/64636 
est during the first 1 to 2 years after first examination. 
Survival rates at 1 year has been reported to be 75 % ; 
at 5 years it has declined to 65 % .3 However, predic- 
tors of outcome have been variable and inconsistent. 
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